|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||99.91 / 187.45|
Those rattles you hear on the COVID, Fed and political fronts are reasons to tread carefully in the markets.
Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.
Ending the pandemic swiftly appears unlikely, so here's how to look at key stocks and sectors right now -- especially as concerns of new lockdowns grow.
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
Here's an update of our investment themes on these companies.
The early stages of the pandemic hurt sales at many biotech companies, but there are signs that revenue streams are picking back up.
Let's check out the charts of this drug maker that raised its full-year 2020 revenue guidance.
Tutor Perini, Beazer Homes and Alexion Pharmaceuticals all turned in solid results in the face of the pandemic.
I continue to shuttle new money into the market on declines using buy-write option strategies.
I've stayed primarily to those names that have plenty of cash on the balance sheet and should be just fine once saner heads prevail.
Alexion Pharmaceuticals and Lantheus Holdings are interesting names at current trading levels.
Charts of the Boston-based biotech to do not provide a compelling case to buy the stock.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
The names include a veterinary drug concern plus companies with successful drugs on the market.